nect Biopharma (US:CNTB) Jin Rong Jie·2025-08-21 14:08Core Viewpoint - Conformant Biopharma (CNTB) has experienced a significant decline in revenue and net profit, indicating potential challenges in its financial performance and operational efficiency [1] Financial Performance - As of June 30, 2025, Conformant Biopharma reported total revenue of $48,000, a year-over-year decrease of 99.8% [1] - The company recorded a net profit attributable to shareholders of -$23.17 million, reflecting a year-over-year decline of 476.52% [1] - Basic earnings per share were reported at -$0.42 [1] Stock Performance - On August 21, CNTB's stock price increased by 3.22%, reaching $1.724 per share [1] - The trading volume on that day was $23,700, with a total market capitalization of $96.053 million [1] Company Overview - Conformant Biopharma is a biopharmaceutical company with clinical-stage products and a global presence [1] - The company develops innovative therapies through its proprietary T-cell function modulation platform, aimed at improving the quality of life for patients with inflammatory immune diseases [1]